Article ID Journal Published Year Pages File Type
10911487 Lung Cancer 2012 8 Pages PDF
Abstract
These meta-analyses suggest that ESAs reduce transfusions without increasing mortality or disease progression in lung cancer patients undergoing chemotherapy.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses
Authors
, , , , , , , ,